| Title:
|
Visual and anatomical outcomes of spironolactone therapy in chronic central serous chorioretinopathy
|
| Author(s):
|
Khalil Ghasemi Falavarjani MD,1 Anahita Amirsardari MD, Abbas Habibi MD, Acieh Eshaghi MD, Kaveh Abri Aghdam MD
|
| Presentation Type:
|
Oral
|
| Subject:
|
Retina and Retinal Cell Biology
|
| Others:
|
|
|
Presenting Author:
|
|
| Name:
|
Kaveh Abri aghdam
|
| Affiliation :(optional)
|
1 Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences
|
| E mail:
|
kaveh_abri@yahoo.com
|
| Phone:
|
|
|
Mobile: |
9120889505
|
|
Abstract (Max 200 words)
|
|
| Purpose:
|
To assess the effects of spironolactone on chronic central serous chorioretinopathy (CSC).
|
| Methods:
|
In this prospective interventional case series, patients with chronic CSC were treated with spironolactone 25 mg daily for at least 6 weeks. If there was an incomplete resolution of subretinal fluid, the treatment was continued with increasing the dosage to 25 mg twice daily. Primary outcome measure was the changes in maximum subretinal fluid height (SRF) at the final follow-up visit as detected by optical coherence tomography. Secondary outcome measures were the changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT).
|
| Results:
|
Sixteen eyes of 14 patients with chronic CSC were enrolled. Mean follow-up time was 6.4 ± 4.3 months. Baseline BCVA was 0.54 ± 0.44 Logarithm of the minimum angle of resolution (LogMAR) and improved to 0.42 ± 0.43 LogMAR at the final visit (P=0.04). Mean CMT decreased from 282.69 ± 103.23 µm at baseline to 236.75 ± 90.10 µm at final visit (p= 0.11). Mean maximum SRF height reduced from 155.63 ± 95.27 µm at baseline to 77.19 ± 95.68 µm at the final visit (P=0.04). SRF resolved completely in 7 eyes (43.75%).
|
| Conclusion:
|
In eyes with persistent SRF because of CSC, spironolactone therapy was associated with a statistically significant decrease in maximum SRF height and improvement in BCVA.
|
| Attachment:
|
5035CSC.IRAVO.pptx
|